Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial
Clinical Microbiology and Infection (2022) - Comments
pubmed: 36096430  doi: 10.1016/j.cmi.2022.09.001  issn: 1198-743x  issn: 1469-0691 

Payam Tabarsi, Nassim Anjidani, Ramin Shahpari, Masoud Mardani, Araz Sabzvari, Babak Yazdani, Hamidreza Kafi, Newsha Fallah, Ali Ebrahimi, Ali Taheri, Nikolai Petrovsky, Saghar Barati